Wikipedia

Mark G. Lebwohl

(Redirected from Mark Lebwohl)

Mark G. Lebwohl is an American dermatologist and author who is Professor and Chairman Emeritus of the Kimberly and Eric J. Waldman Department of Dermatology and the Dean for Clinical Therapeutics at the Icahn School of Medicine at Mount Sinai in New York City.[1][2]

Mark G. Lebwohl
NationalityAmerican
EducationColumbia University
Harvard Medical School
Years active1983-present
Known forpsoriasis
pseudoxanthoma elasticum
Medical career
Professiondermatologist
InstitutionsThe Mount Sinai Hospital

Lebwohl's books include the book on dermatologic therapy, Treatment of Skin Disease (ISBN 0323036031), as well as Atlas of the Skin and Systemic Disease (ISBN 044306539X). He has authored more than 500 publications,[3][4] multiple book chapters and has been named as one of New York Magazine’s “Best Doctors” every year since the inception of the annual list.[5][6] Dr. Brian S. Kim is director of a Center for Neuroinflammation and Sensation named in Mark Lebwohl's honor at Icahn School of Medicine at Mount Sinai.

Biography

edit

Education

edit

Lebwohl graduated from Columbia University in 1974. He earned his medical degree from Harvard Medical School in 1978 and subsequently completed residencies in both internal medicine and dermatology at the Icahn School of Medicine at Mount Sinai.[4]

Career

edit

In 1983, he was made assistant professor of dermatology at Mount Sinai. In 1997, he was named Chairman of the Department[3] which, under his leadership, has been at the forefront of the management of psoriasis.[7]

Lebwohl was the first to report the cardiac complications of pseudoxanthoma elasticum, and, additionally, he has developed new techniques for diagnosing the disease.[7] He was also the first to use immunomodulators (imiquimod) to treat precancerous skin lesions;[8][9] the first to use topical calcineurin inhibitors to treat psoriasis;[10] and the first to identify interactions between topical vitamin D analogues such as calcipotriol and calcitriol with other topical medications and with ultraviolet light.[11][12][13]

Memberships

edit

Lebwohl has served as president of the New York Dermatological Society, the Manhattan Dermatologic Society, and the New York State Society of Dermatology, and as chairman of the Dermatology Section of the New York Academy of Medicine. He served as chairman of the National Psoriasis Foundation's medical board[14] chairman of the Psoriasis Task Force of the American Academy of Dermatology (AAD) and was a member of the Scientific Assembly Council. He chaired the academy's summer meeting in 2001 in California and the AAD annual meeting in Washington, D.C. in 2004. He was elected to the Board of Directors of the AAD for 2010–2014. In 2020, he was elected to the board of the American Skin Association.[15][16]

Awards and honors

edit

Lebwohl earned Presidential Citations in 2002, 2005 and 2006 from the American Academy of Dermatology.[17] Additional awards include:

  • 1993 Founder's Award, National Psoriasis Foundation[18]
  • 2001 PXE International Award[19]
  • 2003 The Jacobi medallion, Mount Sinai Medical Center
  • 2003 British Medical Association Medical Books Competition[20]
  • Highly commended electronic media award for Treatment of Skin Disease, PDA version.
  • 2005 Distinguished Service Award, American Dermatological Association
  • 2006 Winner, The Society of Authors and the Royal Society of Medicine Book Awards for New Edition of an Edited Book, Treatment of Skin Disease: Comprehensive Therapeutic Strategies (2nd edition)[21]

Publications

edit

Journals

edit

Lebwohl is on the editorial board of the Journal of the American Academy of Dermatology and was the editor of the Dermatology Section of Scientific American Medicine, now called ACP Medicine. He is a founding editor of Psoriasis Forum and was medical editor of the bulletin of the National Psoriasis Foundation, Psoriasis Advance.[13][22][23]

Books

edit
  • Lebwohl M, Heymann WR, Berth-Jones J, Coulson I, editors. Treatment of Skin Disease, 3rd edition (2010). London, Mosby 2nd edition (2006) 1st edition (2002) Also published in electronic versions and in Polish and Portuguese. ISBN 0-7020-3121-6
  • Koo, JM, Lebwohl, MG, Lee, CS. (Eds.). (2009). Moderate-to-Severe Psoriasis. New York: Informa Healthcare. ISBN 1-4200-8867-X
  • Koo JM, Lebwohl MG, Lee CS, editors. Mild-to-Moderate Psoriasis 2nd edition(2008). New York, Informa Healthcare 1st edition (2006) ISBN 1-4200-8860-2
  • Lebwohl MG. The Skin and Systemic Disease: A Color Atlas and Text, 2nd edition (2004). New York, Churchill Livingstone Also published in French. ISBN 0-443-06539-X
  • Lebwohl M. Atlas of the Skin and Systemic Disease (1995). New York, Churchill Livingstone ISBN 0-443-06539-X
  • Lebwohl M, editor. Difficult Diagnoses in Dermatology (1988). New York, Churchill Livingston ISBN 0-443-08460-2
  • Lebwohl M, author, treatment of Skin Disease: Comprehensive Therapeutic Strategies (2013), Saunders; 4 edition, ISBN 0-702-03375-8

Publications

edit

Partial list:

References

edit
  1. ^ Lebwohl, Mark G.; Heymann, Warren R.; Berth-Jones, John; Coulson, Ian (2017-09-19). Treatment of Skin Disease E-Book: Comprehensive Therapeutic Strategies. Elsevier Health Sciences. ISBN 978-0-7020-6913-0.
  2. ^ "Mark Lebwohl". Mount Sinai. Retrieved May 15, 2020.
  3. ^ a b TheDerm.org – Editorial Board and Advisors
  4. ^ a b "Mark Lebwohl, MD - American Osteopathic College of Dermatology (AOCD)". www.aocd.org. Retrieved 2020-05-16.
  5. ^ New York Magazine Best Doctors 2009
  6. ^ American Registry
  7. ^ a b Aufses Jr., Arthur H; Barbara Niss (2002). This House of Noble Deeds. NYU Press. pp. 197–198. ISBN 0-8147-0500-6.
  8. ^ Persaud AN, Shamuelova E, Sherer D, Lou W, Singer G, Cervera C, et al. (2002). "Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis". J Am Acad Dermatol. 47 (4): 553–6. doi:10.1067/mjd.2002.123492. PMID 12271300.
  9. ^ Lebwohl M, Dinehart S, Whiting D, Lee PK, Tawfik N, Jorizzo J, et al. (2004). "Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials". J Am Acad Dermatol. 50 (5): 714–21. doi:10.1016/j.jaad.2003.12.010. PMID 15097955.
  10. ^ Lebwohl M, Freeman AK, Chapman MS, Feldman SR, Hartle JE, Henning A, et al. (2004). "Tacrolimus ointment is effective for facial and intertriginous psoriasis". J Am Acad Dermatol. 51 (5): 723–30. doi:10.1016/j.jaad.2004.07.011. PMID 15523350.
  11. ^ Patel B, Siskin S, Krazmien R, Lebwohl M (1998). "Compatibility of calcipotriene with other topical medications". J Am Acad Dermatol. 38 (6 Pt 1): 1010–1. doi:10.1016/s0190-9622(98)70171-9. PMID 9632021.
  12. ^ Lebwohl M, Hecker D, Martinez J, Sapadin A, Patel B (1997). "Interactions between calcipotriene and ultraviolet light". J Am Acad Dermatol. 37 (1): 93–5. doi:10.1016/s0190-9622(97)70217-2. PMID 9216529.
  13. ^ a b "2020 Real World Dermatology for Residents - Board Immersion". www.cvent.com. Retrieved 2020-05-16.
  14. ^ Suddenly, skin creams cost way more - HT Health
  15. ^ "American Skin Association Announces New Board Member Mark Lebwohl, MD". P&T Community. 2020-04-27. Retrieved 2020-05-16.
  16. ^ "News American Skin Association". www.americanskin.org. Retrieved 2020-05-16.
  17. ^ "Dermira's Co-founder and Chief Medical Officer, Eugene A. Bauer, M.D., Receives Presidential Citation from the American Academy of Dermatology". investor.dermira.com. Retrieved 2020-05-16.
  18. ^ "National Psoriasis Foundation honors Dr. Mark G. Lebwohl, renowned dermatologist and psoriasis expert | National Psoriasis Foundation". www.psoriasis.org. Retrieved 2020-05-16.
  19. ^ "People § The Dermatology Summit". www.dermsummit.com. Retrieved 2020-05-16.
  20. ^ British Medical Association Medical Books Archived 2015-06-07 at the Wayback Machine
  21. ^ Society of Authors
  22. ^ WebMD
  23. ^ Business Week
edit
Retrieved from "https://en.wikipedia.org/w/index.php?title=Mark_G._Lebwohl&oldid=1186438298"